PAREA - Science

What. A. Day!

There's a real buzz in the air at regarding the future of psychedelic medicine.
The cherry on top was meeting both a forefather and pioneer of the psychedelic space, Rick Doblin of MAPS!

Excited to learn from our friends at MAPS 🇺🇸 and MAPS 🇪🇺

The European Research Council (ERC) is supportive of psychedelic research and the ECR's Lionel Thelen told the audience that psychedelic science will bring breakthrough outcomes to European Healthcare.

What a fantastic start to ICPR 2022, Shaya Love just facilitated an in-depth and critical discussion about the intersection of psychedelic research, treatments, and investment. With:

Elliot Marseille - Global Initiative for Psychedelic Science Economics
Doug Drysdale - Cybin
Robert Schoevers - University of Groningen
and our Founder Tadeusz Hawrot

We are excited to announce that PsyPAN Global have joined PAREA!

PsyPAN are a network of psychedelic clinical trial and treatment participants, providing mutual peer support and a strong participant voice to help establish a model of best practice across the global psychedelic sector.

With their assistance, we are better able to represent patients that have undergone psychedelic-assisted psychotherapy by listening to those that have experienced this medicine first-hand.

PsyPAN - Psychedelic Participant Advocacy Network Improving participant safety and wellbeing by building best practice across all levels of the global psychedelic sector.

PAREA very much welcomes a recent announcement by the European Commission’s President to have “a comprehensive approach to mental health” at the EU level.

This will be an opportunity for the psychedelics community to further spotlight the recent scientific advances and help to prepare for the adoption of those treatments in the near future.

Very pleased to learn at the meeting with the EU drug agency (EMCDDA) that they are working on a project to facilitate a greater understanding of developments in the area of psychedelic substances for medical use.

A related publication is expected around April next year.

Very productive and promising exchange today at PAREA’s meeting with Dr. Steffen Thirstrup, CMO at the EMA. Europe is lagging behind and EMA is exploring taking a leadership role to bring various EU institutions, scientists, and civil society groups together to explore the future of psychedelic science and therapies in Europe.

There are a number of European-specific challenges that psychedelic medicines will face in the coming years.
However, the EC is conducting a major revision of their pharma strategy, Mr Hawrot explains below:

Move over USA 🇺🇸, Europe 🇪🇺 is coming through!

Webinar: Overcoming Roadblocks Making Psychedelic-Assisted Therapy a Reality Learn about when and how psychedelic-assisted therapy becomes a reality. What are the legislative and regulatory roadblocks, and how Chris Koddermann (ITPRI ...

It was great to meet with Alex Saliba yesterday as well as reps from the European Commission (DG Research) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Today PAREA is meeting with more MEPs to expedite Europe's transition to the psychedelic mainstream!

PAREA representatives met in a virtual space with the European Commission’s Directorate General for Health – DG SANTE which was represented by Andrzej Rys, Director for Health Systems, Medical Products and Innovation and Anthony Rodiadis, Policy Officer, Medicines: Policy, Authorisation and Monitoring.

SANTE – who is currently performing an extensive revision of the EU General Pharmaceutical Legislation - requested additional information on the psychedelic-assisted therapies, which could feed into the revision process that is due to be concluded by the end of 2022.

Following PAREA’s suggestion to organize an EU institution-led workshop exploring the future of psychedelics in Europe, SANTE advised that PAREA engages with EMA in this regard. EMA would be best placed to organize such an event with the US NIH/FDA and in collaboration with other EU institutions.

We will be taking part in the Interdisciplinary Conference on Psychedelic Research (ICPR).

Our founder - Tadeusz Hawrot will be helping fellow panellists answer the question - When will psychedelic-assisted therapy become a reality in Europe and the US?
https://us02web.zoom.us/webinar/register/WN_vijD2u8dSMC2WW99rzeKww

European health systems are not prepared for Psychedelic-assisted psychotherapy - a lot remains to be done to pave the way for their effective rollout and to build a proper medical oversight into the psychedelic model.

Without adequate actions, psychedelic-assisted psychotherapy may not reach patients who need it or may drive them to seek unregulated underground therapy as psychedelics’ medical properties are coming into mainstream knowledge. The work must start now to ensure equitable, timely, affordable, safe and legal access to psychedelic-assisted psychotherapy in the near future. Patients should have them covered within their existing healthcare framework, where they live, by a trained therapist they trust, and paid by healthcare insurance. Otherwise, those most in need will be left without access, including in lower-income and socioeconomically deprived communities, which are disproportionately affected by mental health problems and addictions.

The Psychedelic Access and Research European Alliance - drugscience.org.uk The Psychedelic Access and Research European Alliance (PAREA) has officially launched with an impressive array of wide-ranging support amongst charities, patient groups, not-for-profits and psychedelic industry partners. Drug Science was an incubator for the PAREA collective. We recognised that to e...

The US Drug Enforcement Agency recently withdrew a proposal to ban 5 psychedelic substances thanks to an expert submission from PAREA chair - Prof Nutt.

We welcome this decision and hope that other regulators in Europe and the UK listen to the experts!

The Drug Enforcement Agency listens to psychedelic experts - drugscience.org.uk By Professor David Nutt and James Bunn The Drug Enforcement Agency (DEA) recently withdrew a proposal to ban five psychedelic substances: 4-Hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alphamethyltryptamine (5-MeO-AMT), N-Isopropyl-5-Methoxy-N-Methyltryptamine (5-MeO-MiPT), N,N-Diethyl-5...

Tadeusz Hawrot is interviewed at the European Academy of Neurology 2022 Congress in Vienna, Austria for the Video Journal of Neurology.

Find out about the promising impact of psychedelics to treat traumatic brain injury, PTSD, & cluster headaches. 👇

Videos — LAUNCH Recordings Skip to Videos All | VJNeurology | VJNeurology, • 03/08/2022 PAREA: psychedelic-assisted therapies in Europe This video was recorded at the 8th Congress of the European Academy of Neurology in Vienna VJNeurology, • 03/08/2022 The promise of psychedelic-assisted therapies This video wa...

Whilst the US 'anticipates' the medicalisation of **A and , PAREA is putting together a joint statement to EU policy makers outlining the key priorities for integrating psychedelic-assisted psychotherapy in European healthcare systems. 🇪🇺

Biden Administration Plans for Legal Psychedelic Therapies Within Two Years A letter from the Health and Human Services Department discloses the anticipated FDA approval of M**A and psilocybin treatments.

PAREA recently met with the Innovative Health Initiative a public-private partnership between the European Union and the European life science industries with a budget of EUR 2.4 billion.

At the meeting, we introduced PAREA and explored possible areas for future collaboration with Hugh Laverty, Head of Scientific Operations and Elisabetta Vaudano, Principal Scientific Manager & Responsible Strategic Area Neuroscience.

We discussed methods to translate health research and innovation into tangible benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research.

With more and more mainstream media coverage about the healing potential of medical psychedelics, it is becoming increasingly difficult for policymakers to ignore the evidence regarding the efficacy of these substances.

The screenshot below is from POLITICO's morning Healthcare round-up

Join me at this September 21st to learn how we can make psychedelic therapies a reality.

Get €100 off your ticket by using code TAD100

https://icpr-conference.com/business

We are pleased to announce that the EU4 Health Programme recognised PAREA's consultation on the need to incentivise innovation in the mental health space with cutting-edge science such as psychedelic-assisted psychotherapy.
1/3
https://parea.science/news

Despite the fact we only launched last week, our Chair Professor David Nutt has been lobbying for drug policy reform in Europe for some time now!

In 2017, Prof Nutt explained to TEDX Brussels how psychedelics could help people overcome depression.
Watch below:
https://youtu.be/WOxSQHtJWlo

How can illegal drugs help our brains | David Nutt | TEDxBrussels "Talk covers the wonderous complexity of the brain – the most complex organ in the universe – but one which often goes wrong – so that the cost of brain diso...

In case you missed the launch of PAREA we have uploaded the recording of our launch event to our new Youtube channel!

Featuring:

Dr. Thomas Insel
Prof David Nutt
Prof Gitte Knudsen
and more!

You can find this video along with more information below:
https://parea.science/launched

The is seeking the opinions of stakeholders about current and future EU health priorities, strategic orientations & key health needs.

PAREA submitted a contribution to this consultation arguing that psychedelic-assisted psychotherapy ought to be a key priority.

After we officially launched yesterday and celebrated our zeroth birthday 🎂 we are proud to present the 'PAREA - Call to Action'

Below you can find a full recording of the event itself and our call to action.
https://parea.science/launched

PAREA officially launched — LAUNCH PAREA officially launched, with a Call to Action to EU policy makersOn 23 June 2022, the Psychedelic Access and Research European Alliance – PAREA, was officially launched at a virtual event: Preparing Europe for Novel Psychedelic-Assisted Therapies. Keynote Address was delivered by Dr Thomas Inse...

PAREA has officially launched! 🎉

To celebrate our launch, our Founder was recently interviewed by Parliament Magazine to discuss our Call to Action for European decision makers-bringing together our key priorities and policy asks. 📣 🇪🇺

https://www.theparliamentmagazine.eu/news/article/preparing-europe-for-psychedelic-assisted-therapies

Preparing Europe for psychedelic-assisted therapies Launching a Call to Action to EU policy makers, PAREA’s Tadeusz Hawrot and MEP Sara Cerdas want to see greater research into the potential of psych...

The inaugural launch of PAREA is starting in 30 minutes' time.

To learn more about the future of psychedelic-assisted psychotherapy in Europe join our free webinar below:
https://zoom.us/j/98137842830

Join our Cloud HD Video Meeting Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom Rooms is the original software-based conference room solution used around the world in board, confer...

Recently, Stephanie Price of Psychedelic Health sat down with our Founder Tadeusz Hawrot to discuss how PAREA will work with policymakers to develop and preserve high-quality standards and rigorous training to ensure that participants in Psychedelic-assisted psychotherapy are safe.

https://psychedelichealth.co.uk/2022/06/20/alliance-launches-to-advance-psychedelic-healthcare-in-europe/

Alliance launches to advance psychedelic healthcare in Europe Psychedelic Health speaks to the founder of the Psychedelic Access and Research European Alliance (PAREA), Tadeusz Hawrot, about how the organisation aims to facilitate discussions around psychedelic healthcare in Europe.

For the first time, in known history, EU policy recommendations were made featuring psychedelic-assisted psychotherapy thanks to our Founder Tadeusz Hawrot.

”New models of innovative/unusual treatments when they target unmet needs or vulnerable situations, for instance, psychedelic assisted therapies for brain disorders, which constitute a paradigm shift in the pharmacological space because these therapies will need to be registered as both a medicinal product and therapy.”

https://parea.science/news

About 1 — Parea News and Events Preparing Europe for Novel Psychedelic-Assisted Therapies 23rd June 2022 from 14:00 - 16:00 (CEST) Launch event for the Psychedelic Access and Research European Alliance (PAREA) more details Agenda pdf Joint Statement on an Inclusive Pharmaceutical Strategy June 16th, 2022For the fir...

We are excited to be joined by Tim Raemaekers of the European Commission DG Research & Innovation for our inaugural event on June 23rd 2022

If you have not yet signed up for this event, we recommend doing so soon as there are only 20% of tickets left!

https://www.eventbrite.co.uk/e/preparing-europe-for-novel-psychedelic-assisted-therapies-tickets-355131506897

Preparing Europe for Novel Psychedelic-Assisted Therapies Launch event for the Psychedelic Access and Research European Alliance (PAREA)

Join us on June 23rd for the inaugural launch of the Psychedelic Access and Research European Alliance.
Psychedelic-assisted therapies (PAT) show a promise of being a potent new class of treatments for mental, neurological and substance use disorders, as suggested by the rapidly growing, rigorous, and compelling body of research.
The renaissance of research into the neuroscience and therapeutic applications of PAT represents one of the most promising and important initiatives in brain science and neuropsychopharmacology in recent times, especially given the huge unmet needs in the therapeutic areas that they promise to treat.
At the same time, much has to be done in Europe to start accommodating those advances and to accelerate the safe and responsible integration of PAT into EU healthcare systems in the years to come. This work must start now.
We will be joined by:
Dr Thomas Insel
Professor David Nutt
Dr Sara Cerdas
and Professor Gitte Moos Knudsen
https://www.eventbrite.co.uk/e/preparing-europe-for-novel-psychedelic-assisted-therapies-tickets-355131506897

Preparing Europe for Novel Psychedelic-Assisted Therapies Launch event for the Psychedelic Access and Research European Alliance (PAREA)

PAREA recently provided recommendations on future areas for excellent, innovative and translational brain research in Europe for both psychiatric and neurological disorders. We hope that the SEBRA framework will guide future research investments in Europe.
https://www.ebra.eu/sebra/

We are very pleased to announce that Pain Alliance Europe has joined PAREA as a member and their President - Deirdre Ryan will be joining Professor David Nutt as a Co-Chair of this group.
Psychedelics could be a useful tool for some patients' pain management.
https://pae-eu.eu/

The renaissance of research into the neuroscience and therapeutic applications of -assisted therapy represents one of the most promising and important initiatives in brain science and neuropsychopharmacology in recent times.

https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/13437-A-New-European-Innovation-Agenda/F3257827_en

ec.europa.eu

Tadeusz Hawrot was asked to attend a joint meeting of the sub-group on Cancer to submit evidence about how psychedelic medicines might be integrated into European Union healthcare systems to alleviate the burden that cancer has on European societies.
https://parea.science/news

PAREA CEO - Tadeusz Hawrot will be speaking at the upcoming conference about implementing a modern, rational, & ethically responsible integration of psychedelic-assisted therapies into European mainstream mental health services.
Sign up here: https://microdose.buzz/shop/events/psychedelic-capital/psychedelic-capital-may-2022/

Looking forward to hearing about the future of psychedelic healthcare at next week at the National Gallery, London.
https://www.eventbrite.co.uk/e/psych-symposium-london-tickets-223998785397?aff=Panelassets

PSYCH Symposium: London PSYCH Symposium: London will be hosted at the iconic National Gallery on Wednesday, 11 May 2022.

The Psychedelic Access and Research European Alliance (PAREA) official launch is on the horizon
Follow PAREA for updates about the latest developments in the European psychedelic space
**A *D

https://parea.science/about

PAREA - Science added a button to help you learn more about them.

PAREA - Science updated their business hours.